上海医药(02607.HK)塞来昔布胶囊获批准生产

阿斯达克财经08-06

上海医药(02607.HK) 公布，控股子公司常州制药厂的塞来昔布胶囊近日收到国家药监局颁发药品注册证书，换言之该产品已获批准可生产。

塞来昔布胶囊为环氧化酶-2(COX-2)特异性抑制剂，通过抑制COX-2从而抑制前列腺素的生成，是全球首款选择性非甾体抗炎镇痛药物。截至目前，集团针对该药品已投入研发费用约1,084.02万元人民币。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-06 16:25。)

AASTOCKS新闻

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2457401341?lang=zh_CN&edition=full","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20210429113037816_s.jpg","is_english":false,"pubTime":"2024-08-06 17:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2457401341","market":"fut","top_or_hot":-1,"title":"上海医药(02607.HK)塞来昔布胶囊获批准生产","media":"阿斯达克财经","content":"<html><body><div> <span> <p><a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607.HK)<span> </span>公布，控股子公司常州制药厂的塞来昔布胶囊近日收到国家药监局颁发药品注册证书，换言之该产品已获批准可生产。<br/><span></span><br/>塞来昔布胶囊为环氧化酶-2(COX-2)特异性抑制剂，通过抑制COX-2从而抑制前列腺素的生成，是全球首款选择性非甾体抗炎镇痛药物。截至目前，集团针对该药品已投入研发费用约1,084.02万元人民币。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-06 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>上海医药(02607.HK)塞来昔布胶囊获批准生产</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n上海医药(02607.HK)塞来昔布胶囊获批准生产\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">阿斯达克财经</strong><span class=\"h-time small\">2024-08-06 17:37</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><div> <span> <p><a href=\"https://laohu8.com/S/601607\">上海医药</a>(02607.HK)<span> </span>公布，控股子公司常州制药厂的塞来昔布胶囊近日收到国家药监局颁发药品注册证书，换言之该产品已获批准可生产。<br/><span></span><br/>塞来昔布胶囊为环氧化酶-2(COX-2)特异性抑制剂，通过抑制COX-2从而抑制前列腺素的生成，是全球首款选择性非甾体抗炎镇痛药物。截至目前，集团针对该药品已投入研发费用约1,084.02万元人民币。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-06 16:25。)</p><div></div>AASTOCKS新闻 </span> </div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1369349/latest-news/AAFN\">阿斯达克财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0012","symbol_name":"证金概念","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1369349/latest-news/AAFN","article_id":"2457401341","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20210429113037816_s.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2457401341","pubTimestamp":1722937020,"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"上海医药(02607.HK) 公布，控股子公司常州制药厂的塞来昔布胶囊近日收到国家药监局颁发药品注册证书，换言之该产品已获批准可生产。塞来昔布胶囊为环氧化酶-2(COX-2)特异性抑制剂，通过抑制COX-2从而抑制前列腺素的生成，是全球首款选择性非甾体抗炎镇痛药物。截至目前，集团针对该药品已投入研发费用约1,084.02万元人民币。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-06 16:25。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"601607":"上海医药","BK0012":"证金概念","BK0196":"行业龙头","BK0175":"白马股","BK0099":"上海本地重组","BK0097":"医药电商","BK0020":"浦东新区","02607":"上海医药","BK0184":"上海国资改革","BK0188":"融资融券","BK0209":"零售","BK1197":"保健护理产品经销商","BK0183":"MSCI概念","BK0187":"一线龙头","BK0028":"国家队"},"translate_title":"Shanghai Pharmaceuticals (02607. HK) Celecoxib Capsules Approved for Production","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"601607":1,"02607":1},"content_text":"上海医药(02607.HK) 公布，控股子公司常州制药厂的塞来昔布胶囊近日收到国家药监局颁发药品注册证书，换言之该产品已获批准可生产。塞来昔布胶囊为环氧化酶-2(COX-2)特异性抑制剂，通过抑制COX-2从而抑制前列腺素的生成，是全球首款选择性非甾体抗炎镇痛药物。截至目前，集团针对该药品已投入研发费用约1,084.02万元人民币。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2024-08-06 16:25。)AASTOCKS新闻","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2457401341"}